View Item 

Show simple item record

Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence
dc.contributor.authorBarrett, Terrance D.en_US
dc.contributor.authorHennan, James K.en_US
dc.contributor.authorFischbach, Peter S.en_US
dc.contributor.authorO'Neill, Brian P.en_US
dc.contributor.authorDriscoll, Edward M.en_US
dc.contributor.authorLucchesi, Benedict Roberten_US
dc.date.accessioned2010-06-01T20:48:33Z
dc.date.available2010-06-01T20:48:33Z
dc.date.issued2001-04en_US
dc.identifier.citationBarrett, Terrance D; Hennan, James K; Fischbach, Peter S; O'Neill, Brian P; Driscoll, Edward M; Lucchesi, Benedict R (2001). "Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence." British Journal of Pharmacology 132(7): 1493-1500. <http://hdl.handle.net/2027.42/73908>en_US
dc.identifier.issn0007-1188en_US
dc.identifier.issn1476-5381en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73908
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11264243&dopt=citationen_US
dc.format.extent258702 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2001 British Pharmacological Societyen_US
dc.subject.otherTorsades De Pointesen_US
dc.subject.otherProarrhythmiaen_US
dc.subject.otherQT Prolongationen_US
dc.subject.otherClass IIIen_US
dc.subject.otherTedisamilen_US
dc.subject.otherDofetilideen_US
dc.titleTedisamil and dofetilide-induced torsades de pointes, rate and potassium dependenceen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pediatrics and Communicable Diseases, Division of Pediatric Cardiology, University of Michigan Medical School, Ann Arbor, Michigan, MI 48019-0632, U.S.A.en_US
dc.identifier.pmid11264243en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73908/1/sj.bjp.0703967.pdf
dc.identifier.doi10.1038/sj.bjp.0703967en_US
dc.identifier.sourceBritish Journal of Pharmacologyen_US
dc.identifier.citedreferenceANTZELEVITCH, C., SHIMIZU, W., YAN, G.X., SICOURI, S., WEISSSENBURGER, J., NESTERENKO, V.V., BURASHNIKOV, A., DIDIEGO, SAFFITA, J. & THOMAS, G.P. ( 1999 ). The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J. Cardiovasc. Electrophysiol., 10, 1124 – 1152.en_US
dc.identifier.citedreferenceBARGHEER, K., DOBDE, F., KLEIN, H.U., TRAPPE, H.J., FRANZ, M.R. & LICHTLEN, P.R. ( 1994 ). Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium channel-blocking agent. Eur. Heart J., 15, 1409 – 1414.en_US
dc.identifier.citedreferenceBEATCH, G.N., ABRAHAM, S., MACLEOD, B.A. & WALKER, M.J.A. ( 1991 ). Antiarrhythmic properties of tedisamil (KC8857), a putative, transient outward K + channel blocker. Br. J. Pharmacol., 102, 13 – 18.en_US
dc.identifier.citedreferenceBRAY, K. & QUAST, U. ( 1992 ). Differential inhibition by tedisamil (KC 8857) and glibenclamide of the responses to cromakalim and minoxidil sulfate in rat isolated aorta. Naunyn-Schmiedeberg's Arch. Pharmacol., 345, 244 – 250.en_US
dc.identifier.citedreferenceBRIL, A., GOUT, B., BONHOMME, M., LANDAIS, L., FAIVRE, J.F., LINEE, P., POYSER, R.H. & RUFFOLO JR., R.R. ( 1996 ). Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J. Pharmacol. Exp. Therap., 276, 637 – 646.en_US
dc.identifier.citedreferenceBUCHANAN, L.V., KABELL, G., BRUNDER, M.N. & GIBSON, J.K. ( 1993 ). Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J. Cardiovasc. Pharmacol., 22, 540 – 549.en_US
dc.identifier.citedreferenceCHI, L., PARK, J.L., FRIEDRICHS, G.S., BANGLAWALA, Y.A., PEREZ, M.A., TANHEHCO, E.J. & LUCCHESI, B.R. ( 1996 ). Effects of tedisamil (KC-8857) on cardiac electrophysiology an ventricular fibrillation in the rabbit isolated heart model. Br. J. Pharmacol., 117, 1261 – 1269.en_US
dc.identifier.citedreferenceCONNOLLY, S.J. ( 1999 ). Evidence-based analysis of amiodarone efficacy and safety. Circulation, 100, 2025 – 2034.en_US
dc.identifier.citedreferenceDUFF, H.J., FENG, Z.P., FISET, C., WANG, L., LEES-MILLER, J. & SHELDON, R.S. ( 1997 ). [3H]Dofetilide binding to cardiac myocytes: modulation by extracellular potassium. J. Mol. Cell. Cardiol., 29, 183 – 191.en_US
dc.identifier.citedreferenceDUKES, I.D., CLEEMANN, L. & MORAD, M. ( 1990 ). Tedisamil blocks the transient outward and delayed rectifier K + currents in mammalian cardiac and glial cells. J. Pharmacol. Exp. Ther., 254, 560 – 568.en_US
dc.identifier.citedreferenceDUKES, I.D. & MORAD, M. ( 1989 ). Tedisamil inactivates transient outward K + current in rat ventricular myocytes. Am. J. Physiol., 257, H1746 – H1749.en_US
dc.identifier.citedreferenceECHT, E.D., LEE, J.T., MURRAY, K.T., VORPERIAN, V., BORGANELLIT, S.M., CRAWFORD, D.M., FRIEDRICH, T. & RODEN, D.M. ( 1995 ). A randomiszed, double-blind, placebo-controled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J. Cardiovasc. Electrophysiol., 6, 687 – 699.en_US
dc.identifier.citedreferenceECKARDT, L., HAVERKAMP, W., BORGGREFE, M. & BREITHARDT, G. ( 1998 ). Experimental models of torsades de pointes. Caridovasc. Res., 39, 178 – 193.en_US
dc.identifier.citedreferenceFAIVRE, J.F., ROUANET, S. & BRIL, A. ( 1998 ). Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031, and BRL-32872 on protein kinase A-activated chloride current in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol., 3, 551 – 557.en_US
dc.identifier.citedreferenceFISCHBACH, P.S., JOHNSTON, P.V., FRIEDRICHS, G.S. & LUCCHESI, B.R. ( 1999 ). Tedisamil in chronic canine atrial flutter. J. Cardiovasc. Pharmacol., 34, 212 – 218.en_US
dc.identifier.citedreferenceFOX, K.M., HENDERSON, J.R., KASKI, J.C., SACHSE, A., KUESTER, L. & WONNACOTT, S. ( 2000 ). Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker. Heart, 83, 167 – 171.en_US
dc.identifier.citedreferenceFRIEDRICHS, G.S., ABREU, J.N., DRISCOLL JR., E.M., BORLAK, J. & LUCCHESI, B.R. ( 1998 ). Antifibrillatory efficacy of long-term tedisamil administered in a postinfarcted canine model of ischemic ventricular fibrillation. J. Cardiovasc. Pharmacol., 31, 55 – 66.en_US
dc.identifier.citedreferenceFRIEDRICHS, G.S., ABREU, J.N., COUSINS, G.R., CHI, L., BORLAK, J. & LUCCHESI, B.R. ( 1996 ). Tedisamil attenuates ventricular fibrillation in a conscious canine model of sudden cardiac death. J. Cardiovasc. Pharmacol. Therapeut., 1, 313 – 324.en_US
dc.identifier.citedreferenceFROST, L., MORTENSEN, P.E., TINGLEFF, J., PLATOU, E.S., CHRISTIANSEN, E.H. & CHRISTIANSEN, N. ( 1997 ). Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. Int. J. Cardiol., 58, 135 – 140.en_US
dc.identifier.citedreferenceHONDEGHEM, L.M. & SNYDERS, D.J. ( 1990 ). Class III antiarrhyhtmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation, 81, 686 – 690.en_US
dc.identifier.citedreferenceJACKMAN, W.M., FRIDAY, K.J., ANDERSON, J.L., ALIOT, E.M., CLARK, M. & LAZZARA, R. ( 1988 ). The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis. Prog. Cardiovasc. Dis., 31, 115 – 172.en_US
dc.identifier.citedreferenceJOHNA, R., MERTENS, H., HAVEKAMP, W., ECKARDT, L., NIEDERBROKER, T., BORGGGREFE, M. & BREITHARDT, G. ( 1998 ). Clofilium in the isolated perfused rabbit heart: a new model to study proarrhythmia induced by class III antiarrhythmic drugs. Basic Res. Cardiol., 93, 127 – 135.en_US
dc.identifier.citedreferenceKEHOE, R.S., ZHEUTLIN, T.A., DUNNINGTON, C.S., MATTIONI, T.A., YU, G. & SPANGENBERGER, R.B. ( 1990 ). Safety and efficacy of sotalol in patients with drug refractory sustained ventricular tachyarrhythmias. Am. J. Cardiol., 65, 58A – 64A.en_US
dc.identifier.citedreferenceKOWEY, P.K., VANDERLUGHT, J.T. & LUDERER, J.R. ( 1996 ). Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am. J. Cardiol., 78, 46 – 52.en_US
dc.identifier.citedreferenceNEMETH, M., VIRAG, L., HALA, O., VARRO, A., KOVACS, G., THORMAHLEN, D. & PAPP, J.G. ( 1996 ). The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibres. Cardiovasc. Res., 31, 246 – 248.en_US
dc.identifier.citedreferenceORAL, H., SOUZA, J.J., MICHAUD, G.F., KNIGHT, B.P., GOYAL, R., STRICKBERGER, S.A. & MORADY, F. ( 1999 ). Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N. Engl. J. Med., 17, 1910 – 1912.en_US
dc.identifier.citedreferenceREES, S.A., TSUCHIHASHI, K., HEARSE, D.J. & CURTIS, M.J. ( 1993 ). Combined administration of an IK (ATP) activator and I to blocker increases coronary flow independent of effects on heart rate, QT interval and ischaemia-induced ventricular fibrillation in rat. J. Cardiovasc. Pharmacol., 22, 343 – 349.en_US
dc.identifier.citedreferenceSANGUINETTI, M.C. & JURKIEWICZ, N.K. ( 1990 ). Two components of cardiac delayed rectifier K + current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol., 96, 195 – 215.en_US
dc.identifier.citedreferenceSTAMBLER, B.S., BECKMAN, K.J., KADISH, A.H., CAMM, J.A., ELLENBOGEN, K.A., PERRY, K.T. & VANDERLUGT, J.T. ( 1997 ). Acute hemodynamic effects of intravenous ibutilide in patients with without reduced left ventricular function. Am. J. Cardiol., 80, 458 – 463.en_US
dc.identifier.citedreferenceTORP-PEDERSEN, C., MOLLER, M., BLOCH-THOMSEN, P.E., SANDOE, E., EGSTRUP, K., AGNER, E., CARLSEN, J., VIDEBAEK, J., MARCHANT, B. & CAMM, A.J. ( 1999 ). Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New Engl. J. Med., 341, 857 – 865.en_US
dc.identifier.citedreferenceTSUCHIHASHI, K. & CURTIS, M.J. ( 1991 ). Influence of tedisamil on the initiation and maintenance of ventricular fibrillation: chemical defibrillation by Ito blockade. J. Cardiovasc. Pharmacol., 18, 445 – 456.en_US
dc.identifier.citedreferenceWALLACE, A.A., STUPIENSKI III, R.F., BASKIN, E.P., APPLEBY, S.D., KOTHSTEIM, T., GEHRET, J.R., KING, S.W., REMY, D.C. & LYNCH, J.J. ( 1995 ). Cardiac electrophysiological and antiarrhythmic actions of tedisamil. J. Pharmacol. Exp. Ther., 273, 168 – 175.en_US
dc.identifier.citedreferenceYANG, T. & RODEN, D.M. ( 1996 ). Extracellular potassium modulation of drug block of I Kr. Implications for torsade de pointes and reverse use-dependence. Circulation, 93, 407 – 411.en_US
dc.identifier.citedreferenceZABEL, M., HOHNLOSER, S.H., BEHRENS, S., LI, Y.G., WOOSLEY, R.L. & FRANZ, M.R. ( 1997 ). Electrophysiological features of torsades de pointes: insight from a new isolated rabbit heart model. J. Cardiovasc. Electrophysiol., 8, 1159 – 1162.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
sj.bjp.0703967.pdf
Size:
252.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.